BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report

BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report

BackgroundMutations in the human breast cancer susceptibility gene 2 (breast cancer 2, BRCA2) increase the risk of breast, ovarian and other cancers. Olaparib, an oral poly[adenosine diphosphate (ADP)–ribose] polymerase (PARP) inhibitor, is usually prescribed to treat BRCA mutated tumors, especially...

Full description

Bibliographic Details
Main Authors: Zhujun Chen, Kang Wang, Lintao Zhao, Liang Gong
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
Olaparib
lung squamous cell carcinoma
PD-1 inhibitor
BRCA2 mutation
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1190100/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1190100/full

Similar Items